Bausch + Lomb CorpNYSE:BLCOView on Canadian Exchange
- LAST PRICE19.9600
- TODAY'S CHANGE (%)-0.0400 (-0.2000%)
- Bid / Lots18.9400/ 1
- Ask / Lots20.5600/ 1
- Open / Previous Close19.9600 / 20.0000
- Day Range
- 52 Week Range
- Volume616,622
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Sep 16, 2024
DJ Bausch + Lomb Potential Sale Would Benefit Bausch Health Shareholders -- Market Talk, from 12:17PM ET on Monday Sep 16, 2024 by Dow Jones
12:17PM ET on Monday Sep 16, 2024 by Dow JonesDJ Bausch + Lomb Shares Up in Premarket Amid Sale Consideration, from 9:18AM ET on Monday Sep 16, 2024 by Dow Jones
9:18AM ET on Monday Sep 16, 2024 by Dow JonesDJ S&P 500 Futures Flat In Premarket Trading; Nuvalent, Bausch + Lomb Lead, from 7:30AM ET on Monday Sep 16, 2024 by Dow Jones
7:30AM ET on Monday Sep 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Bausch + Lomb Corp | 7.0B | -15.4x | --- |
DENTSPLY SIRONA Inc | 5.3B | -30.2x | --- |
Masimo Corp | 6.5B | 82.6x | -15.37% |
Stevanato Group SpA | 5.8B | 37.5x | --- |
Lantheus Holdings Inc | 7.6B | 18.0x | +35.30% |
Bio Rad Laboratories Inc | 9.2B | -7.0x | --- |
Company Information
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Contact Information
- Headquarters
- 520 Applewood CrescentVAUGHAN, ON, Canada L4K 4B4
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Brenton Saunders
- Chief Financial Officer, Executive Vice President
- Sam Eldessouky
- President of Ophthalmic Pharmaceuticals
- Andrew Stewart
- Executive Vice President, Chief Legal Officer
- A. Robert Bailey
- Executive Vice President - Research & Development, Chief Medical Officer
- Yehia Hashad
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.0B |
|---|---|
Revenue (TTM) | $4.5B |
Shares Outstanding | 352.0M |
Bausch + Lomb Corp does not pay a dividend. | |
Beta | --- |
EPS | $-1.30 |
Book Value | $19.52 |
P/E Ratio | -15.4x |
Price/Sales (TTM) | 1.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | 2.69% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
